Updated Analysis: Effect of Biweekly Dosing Schedule of Trifluridine-Tipiracil (TAS-102) on Rates of Myelosuppression and Maintenance of Therapeutic Efficacy in Patients (pts) with Previously Treated Metastatic Colorectal Cancer (Mcrc).